AWAKN is integrating psychedelic medicine into mainstream mental healthcare in order to address a US$700bn annual problem across the UK and Europe. We work across three divisions - Research, Clinics and Training. Our scientific team is led by Prof David Nutt and Dr Ben Sessa.
Get in touch for more information:
Investor Relations - email@example.com
Media Inquiries - firstname.lastname@example.org